ConductScience.org, home

Gene · 5170

PDPK1: 3-phosphoinositide dependent protein kinase 1

12 sourcesgene-search-2026-11-11-0.2.0

Download JSON
Cite this record

ConductScience Library. PDPK1: 3-phosphoinositide dependent protein kinase 1. Genes, record 5170. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/5170

On this page

Gene

Symbol
PDPK1
HGNC
Name
3-phosphoinositide dependent protein kinase 1
HGNC
NCBI Gene ID
5170
NCBI Gene
HGNC ID
HGNC:8816
HGNC
Ensembl
ENSG00000140992
NCBI Gene
Aliases
PDK1, PRO0461
NCBI Gene
Type
protein-coding
NCBI Gene

Proteins1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated in
O155303-phosphoinositide-dependent protein kinase 155670Ensembl, GeneID, HGNC

Source UniProt

Patents58

Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.

PublicationPublishedSEQ ID NOProteinSource
EP 4650780 A22025-11-196874O15530Espacenet
JP 2025517970 A2025-06-126874O15530Espacenet
JP 2025062604 A2025-04-14306O15530Espacenet
JP 2024123008 A2024-09-104711O15530Espacenet
US 11892452 B22024-02-0697O15530Espacenet
US 11708396 B22023-07-251837O15530Espacenet
US 11696924 B22023-07-1123O15530Espacenet
US 11446398 B22022-09-20306O15530Espacenet
JP 2022524081 A2022-04-27103277O15530Espacenet
US 11016093 B22021-05-2597O15530Espacenet

1 to 10 of 58

See all 58 patents

Drugs2

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
AR-12CHEMBL16505953-phosphoinositide dependent protein kinase-1 inhibitorINHIBITORChEMBL
UCN-01CHEMBL5747373-phosphoinositide dependent protein kinase-1 inhibitorINHIBITORChEMBL

Trials16

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT00978523AR-12PHASE1ClinicalTrials.gov
NCT00301938UCN-01PHASE1ClinicalTrials.gov
NCT00098956UCN-01PHASE22015-09-09ClinicalTrials.gov
NCT00082017UCN-01PHASE22012-08-29ClinicalTrials.gov
NCT00072267UCN-01PHASE2ClinicalTrials.gov
NCT00072189UCN-01PHASE22015-03-02ClinicalTrials.gov
NCT00045747UCN-01PHASE2ClinicalTrials.gov
NCT00045513UCN-01PHASE1/PHASE2ClinicalTrials.gov
NCT00045500UCN-01PHASE1ClinicalTrials.gov
NCT00045175UCN-01PHASE1ClinicalTrials.gov

1 to 10 of 16

See all 16 trials

NIH grants1,622

NIH grants whose papers are about the gene, through NIH's grant-paper links.

GrantTitlePDPK1 papersNewest fiscal year
P30CA016672Cancer Center Support Grant202025
P30CA008748Cancer Center Support Grant102025
ZIABC005708Xenobiotic metabolism, cancer chemoprevention and cancer biomarkers102025
ZIABC005562Xenobiotic receptors72025
P30CA023074University of Arizona Cancer Center - Cancer Center Support Grant62025
P30CA076292Moffitt Cancer Center Support Grant52025
R01CA200709Facilitated recruitment of MYC to chromatin by interaction with WDR542025
P30CA016042Cancer Center Support Grant32025
P30CA016056Roswell Park Cancer Center Support Grant32025
P30CA016058Cancer Center Support Grant32025

1 to 10 of 1,622Source NIH's project files

See all 1,622 nih grants

Papers2,673

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

TitleJournalYearPMIDFound bySource
Mutant p53R273H disrupts PDPK1 homodimerization and contributes to PDPK1 activation.Mol Oncol202642808303PubTator, text miningPubMed
A De Novo 16p13.3 Triplication Underlying Early-Onset Complex Neurodegeneration.Mov Disord202642734088PubTator, text miningPubMed
PDK1 signaling in cancer: Current status and future perspectives.Int J Biol Macromol202642716156PubTator, text miningPubMed
Osthole and matrine suppress malignant progression of lead-exposed NSCLC via regulating cellular homeostasis: A combined network pharmacology and in vitro experimental study.Phytomedicine202642555991PubTator, text miningPubMed
The PDPK1-RSK2 axis as a potential convergent therapeutic vulnerability in B-cell lymphomas.Expert Opin Ther Targets202642489440PubTator, text miningPubMed
Akt inhibitor-IV in estrogen receptor-positive breast cancer cells: cytotoxic, apoptotic, transcriptional, and in-silico comparison with tamoxifen.Anticancer Drugs202642390376PubTator, text miningPubMed
Correction: Targeting 3-phosphoinositide-dependent protein kinase 1 associated with drug-resistant renal cell carcinoma using new oridonin analogs.Cell Death Dis202642259783PubTator, text miningPubMed
Penfluridol directly targets PDPK1 to suppress AKT1 phosphorylation and stabilize CTR1, inducing cuproptosis in colorectal cancer.Acta Pharmacol Sin202642185682PubTator, text miningPubMed
Thr308-dephosphorylated AKT1 licenses SQSTM1-LC3C-mediated antiviral autophagy.Autophagy202642152503PubTator, text miningPubMed
Genomic profile of an IDH-wild-type glioblastoma diagnosed following TNF-α inhibitor therapy: a molecular case study.Front Oncol202642130630PubTator, text miningPubMed

1 to 10 of 2,673

See all 2,673 papers

Sources 12

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
  • GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
  • HGNCCC0
  • NCBI GenePublic domain (US government)
  • NIH's project files and grant-paper linksPublic domain
  • Open TargetsCC0 1.0
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
  • GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
  • HGNCCC0: https://www.genenames.org/about/license/
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this gene from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/genes/v1/5170

GET https://conductscience.org/api/genes/v1/5170/patents?page=2